Microneedle Array for Intradermal Hepatitis Vaccine Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The natural impermeability of the stratum corneum skin layer poses a barrier for intradermal application of hepatitis vaccines, making it difficult for pharmaceutical agents to penetrate effectively, which is a challenge for achieving successful immunization against hepatitis B.
Innovation Solution
A microneedle array formulation comprising polyvinylpyrrolidone (PVP) and HBsAg is used to facilitate intradermal application, where the microneedles penetrate the skin, allowing for the delivery of the hepatitis vaccine directly into the dermis, potentially eliminating the need for adjuvants and ensuring effective antibody generation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional injection methods are used for hepatitis vaccination, then effective immunization can be achieved, but the application process is invasive and requires trained personnel
Solution Approach 1:
The vaccine formulation is segmented into multiple microneedle arrays, each containing multiple microneedles that can be applied simultaneously to the skin. This segmentation allows the complex vaccination process to be divided into simple, repeatable applications that are easier to administer while maintaining effectiveness
Solution Approach 2:
Polyvinylpyrrolidone (PVP) serves as an intermediary substance that enables the HBsAg vaccine antigen to be delivered through microneedles. The PVP forms a matrix that holds the antigen and facilitates its release into the dermis upon skin penetration, bridging the gap between the solid microneedle structure and the liquid vaccine delivery requirement
2Ease of manufacture
If the stratum corneum barrier is intact, then skin protection is maintained, but intradermal delivery of vaccine antigens is prevented
Solution Approach 1:
The microneedle array provides localized penetration through the stratum corneum at specific points, creating temporary channels for vaccine delivery. The local quality of the skin barrier is altered only at the microneedle contact points, allowing intradermal delivery without compromising the overall integrity and protective function of the skin barrier
Solution Approach 2:
The microneedles physically alter the parameter of skin permeability by creating micro-channels through the stratum corneum. This temporary parameter change allows vaccine antigens to pass through the normally impermeable barrier and reach the dermis, after which the channels close and the barrier function is restored
Data Source
AI summary
The present invention relates to a microneedle system (MNS for short) for the intradermal application of a hepatitis vaccine, namely the antigen HBsAg.